Integrated Historical Cash Flow

INBP -  USA Stock  

USD 1.08  0.01  0.92%

Analysis of Integrated Biopharma cash flow over time is an excellent tool to project Integrated Biopharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Issuance Purchase of Equity Shares of 20.4 K or Net Cash Flow from Operations of 3.3 M as it is a great indicator of Integrated Biopharma ability to facilitate future growth, repay debt on time or pay out dividends.Financial Statement Analysis is way more than just reviewing and evaluating Integrated Biopharma prevailing accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Integrated Biopharma is a good buy for the upcoming year.
Please see Risk vs Return Analysis.

Integrated Historical Statements 

 
Refresh

Integrated Biopharma Capital Expenditure

(318,289)Share

About Integrated Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Integrated balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Integrated's non-liquid assets can be easily converted into cash.

Integrated Biopharma Cash Flow Chart

Integrated Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Integrated Biopharma Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
Integrated Biopharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Net Cash Flow from Operations of 3.05 Million. As of 25th of October 2021, Share Based Compensation is likely to grow to about 249.2 K, while Capital Expenditure is likely to drop (318.3 K).

Issuance Purchase of Equity Shares

A component of Net Cash Flow from Financing representing the net cash inflow (outflow) from common equity changes. Includes additional capital contributions from share issuances and exercise of stock options; and outflow from share repurchases.

Net Cash Flow from Financing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from financing activities; from continuing and discontinued operations. Principal components of financing cash flow are: issuance (purchase) of equity shares; issuance (repayment) of debt securities; and payment of dividends & other cash distributions.

Net Cash Flow from Investing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from investing activities; from continuing and discontinued operations. Principal components of investing cash flow are: capital (expenditure) disposal of equipment Capital Expenditure; business (acquisitions) disposition Net Cash Flow Business Acquisitions and Disposals and investment (acquisition) disposal [NCFInv].

Net Cash Flow from Operations

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from operating activities; from continuing and discontinued operations.
Most accounts from Integrated Biopharma cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Integrated Biopharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.Integrated Biopharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Net Cash Flow from Operations of 3.05 Million. As of 25th of October 2021, Share Based Compensation is likely to grow to about 249.2 K, while Capital Expenditure is likely to drop (318.3 K).

Integrated Biopharma cash flow statement Correlations

Integrated Biopharma Account Relationship Matchups

Integrated Biopharma cash flow statement Accounts

201620172018201920202021 (projected)
Capital Expenditure(327 K)(241 K)(414 K)(211 K)(295 K)(318.29 K)
Depreciation Amortization and Accretion393 K348 K774 K772 K826 K754.73 K
Net Cash Flow or Change in Cash and Cash Equivalents(263 K)96 K247 K(73 K)(192 K)(197.05 K)
Issuance Repayment of Debt Securities(494 K)(973 K)84 K(1.31 M)(3.07 M)(3.15 M)
Net Cash Flow from Financing(333 K)(830 K)341 K(1.3 M)(3.04 M)(3.12 M)
Net Cash Flow from Investing(327 K)(242 K)(422 K)(110 K)(199 K)(214.71 K)
Net Cash Flow from Operations397 K1.17 M328 K1.34 M3.05 M3.29 M
Share Based Compensation49 K14 K144 K59 K231 K249.24 K

Integrated Biopharma Investors Sentiment

The influence of Integrated Biopharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Integrated. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - INBP

Integrated Biopharma Investor Sentiment

Most of Macroaxis users are currently bullish on Integrated Biopharma. What is your judgment towards investing in Integrated Biopharma? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Integrated Biopharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Integrated Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integrated Biopharma. If investors know Integrated will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integrated Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.